AP NEWS

Global Myelofibrosis Therapeutics Market 2018-2022| High Off-Label Prescription to Boost Demand | Technavio

December 28, 2018

LONDON--(BUSINESS WIRE)--Dec 28, 2018--The global myelofibrosis therapeutics market is expected to post a CAGR of over 7% during the period 2018-2022, according to the latest market research report by .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181228005086/en/

Technavio has published a new market research report on the global myelofibrosis therapeutics market from 2018-2022. (Graphic: Business Wire)

A key factor driving the growth of the global myelofibrosis therapeutics market is the increasing number of companies entering the myelofibrosis segment. There were very few companies investing in the R&D of myelofibrosis therapies before the launch of JAKAVI/JAKAFI. After the sales of JAKAVI/JAKAFI resulted in high revenue growth of Incyte pharmaceuticals, several manufacturers have entered the market. Novartis acquired the exclusive rights of ruxolitinib outside the US from lncyte, and currently, both the companies are successfully marketing ruxolitinib for myelofibrosis. Hence, the emergence of a surge of new companies will propel the growth of the market during the forecast period.

This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period.

This report is available at a USD 1,000 discount for a limited time only:

In this report, Technavio highlights the high off-label prescription as one of the key emerging trends in the global myelofibrosis therapeutics market:

Global myelofibrosis therapeutics market: High off-label prescription

Over the years, the patients with myelofibrosis were treated with drugs such as hydroxyurea, immunomodulators thalidomide, lenalidomide, and steroids. At present, physicians continue to prescribe these drugs to the patients to ease the symptoms and prolong the survival. However, these drugs are considered as off-label by FDA because they are prescribed for conditions other than the ones for which they have been approved. For instance, Pegasys, a pegylated form of interferon alpha by Roche, is approved for Hepatitis C, but because of its efficacy and tolerance in the Phase II studies of MPN, it is being prescribed more often for MPN. Thus, the high off-label prescription will impact market growth.

“Apart from the increasing number of companies entering the myelofibrosis segment, other factors such as the need for disease-modifying drugs for myelofibrosis, and the initiatives by government and non-government organizations are expected to propel the growth of the global myelofibrosis therapeutics market during the forecast period,” says a senior research analyst at Technavio.

Global myelofibrosis therapeutics market: Segmentation analysis

This market research report segments the global myelofibrosis therapeutics market by type of treatment (drug therapy, blood transfusion, HSCT, and androgen therapy) and geographical regions (APAC, EMEA, and the Americas).

The Americas region led the market in 2017 with a market share of close to 52%, followed by EMEA and APAC respectively. Although the EMEA region held a market share lesser than the Americas in 2017, it is expected to register the highest incremental growth during the forecast period.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181228005086/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 12/28/2018 12:20 PM/DISC: 12/28/2018 12:20 PM

http://www.businesswire.com/news/home/20181228005086/en

AP RADIO
Update hourly